PolTREG S.A. (PTG) - Total Liabilities
Based on the latest financial reports, PolTREG S.A. (PTG) has total liabilities worth zł30.71 Million PLN (≈ $8.45 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PolTREG S.A. cash flow conversion to assess how effectively this company generates cash.
PolTREG S.A. - Total Liabilities Trend (2018–2024)
This chart illustrates how PolTREG S.A.'s total liabilities have evolved over time, based on quarterly financial data. See PolTREG S.A. (PTG) shareholders funds for net asset value and shareholders' equity analysis.
PolTREG S.A. Competitors by Total Liabilities
The table below lists competitors of PolTREG S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Leyand International Tbk
JK:LAPD
|
Indonesia | Rp152.73 Billion |
|
Kidoz Inc
V:KIDZ
|
Canada | CA$2.19 Million |
|
Calgro M3 Holdings Ltd
JSE:CGR
|
South Africa | ZAC1.96 Billion |
|
TMK Energy Ltd
AU:TMK
|
Australia | AU$532.78K |
|
Termorex
WAR:TRR
|
Poland | zł4.21 Million |
|
JPEL Private Equity Ltd
LSE:JPEL
|
UK | $443.00K |
|
Aneka Jaringan Holdings Bhd
KLSE:0226
|
Malaysia | RM179.27 Million |
|
Murudeshwar Ceramics Limited
NSE:MURUDCERA
|
India | Rs2.11 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down PolTREG S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PTG company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PolTREG S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PolTREG S.A. (2018–2024)
The table below shows the annual total liabilities of PolTREG S.A. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł33.15 Million ≈ $9.12 Million |
-16.26% |
| 2023-12-31 | zł39.58 Million ≈ $10.89 Million |
+77.77% |
| 2022-12-31 | zł22.27 Million ≈ $6.13 Million |
+263.93% |
| 2021-12-31 | zł6.12 Million ≈ $1.68 Million |
+79.41% |
| 2020-12-31 | zł3.41 Million ≈ $938.48K |
-50.23% |
| 2019-12-31 | zł6.85 Million ≈ $1.89 Million |
-29.37% |
| 2018-12-31 | zł9.70 Million ≈ $2.67 Million |
-- |
About PolTREG S.A.
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland.